Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

(2016) Anthony T. Podany et al.   CLINICAL PHARMACOKINETICS

Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System

(2016) Luc Bertrand et al.   CURRENT PHARMACEUTICAL DESIGN

Neuropsychiatric Effects of HIV Antiviral Medications

(2016) Glenn J. Treisman et al.   DRUG SAFETY

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis

(2016) S Teeraananchai et al.   HIV MEDICINE

The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update

(2016) Meng-Chen Lu et al.   MEDICINAL RESEARCH REVIEWS

HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment

(2016) Deanna Saylor et al.   Nature Reviews Neurology

Gartanin Protects Neurons against Glutamate-Induced Cell Death in HT22 Cells: Independence of Nrf-2 but Involvement of HO-1 and AMPK

(2016) Xiao-yun Gao et al.   NEUROCHEMICAL RESEARCH

Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics

(2016) Ankit Shah et al.   NEUROTOXICITY RESEARCH

Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice

(2016) Vir B. Singh et al.   Scientific Reports

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

(2016) Steve Kanters et al.   Lancet HIV

Psychiatric disorders after starting dolutegravir

(2015) Farid Kheloufi et al.   AIDS

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

(2015) Juan M Tiraboschi et al.   ANTIVIRAL THERAPY

Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells

(2015) Marlene Weiß et al.   Cardiovascular Toxicology

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance

(2015) Amedeo Capetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study

(2015) Ned Sacktor et al.   NEUROLOGY

Decreased Mitochondrial Function Among Healthy Infants Exposed to Antiretrovirals During Gestation, Delivery and the Neonatal Period

(2015) Antoni Noguera-Julian et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response

(2015) Aude De Gassart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV infection and antiretroviral therapy lead to unfolded protein response activation

(2015) Mariana Borsa et al.   Virology Journal

Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity

(2015) M Halliday et al.   Cell Death & Disease

HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?

(2015) Ronald A Cohen et al.   Alzheimers Research & Therapy

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

(2014) A. Blas-Garcia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of Platelet-Monocyte Complexes in HIV-1-Infected Individuals: Possible Role in HIV-Associated Neuroinflammation

(2014) M. V. Singh et al.   JOURNAL OF IMMUNOLOGY

Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases

(2014) Claudio Hetz et al.   NATURE REVIEWS NEUROSCIENCE

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

(2014) E. C. Caniglia et al.   NEUROLOGY

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

(2014) I. Grant et al.   NEUROLOGY

Heme oxygenase in neuroprotection: from mechanisms to therapeutic implications

(2014) Jijun Chen   REVIEWS IN THE NEUROSCIENCES

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

Darunavir: A Review of Its Use in the Management of HIV-1 Infection

(2013) Emma D. Deeks   DRUGS

Targeting the unfolded protein response in neurodegeneration: A new approach to therapy

(2013) Mark Halliday et al.   NEUROPHARMACOLOGY

Pharmacological brake-release of mRNA translation enhances cognitive memory

(2013) Carmela Sidrauski et al.   eLife

Infection of human pericytes by HIV-1 disrupts the integrity of the blood-brain barrier

(2012) Shinsuke Nakagawa et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Barrier Mechanisms in the Developing Brain

(2012) Norman R. Saunders et al.   Frontiers in Pharmacology

Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair?

(2012) Ana A. Baburamani et al.   Frontiers in Physiology

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

(2011) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Dimethyl Fumarate, an Immune Modulator and Inducer of the Antioxidant Response, Suppresses HIV Replication and Macrophage-Mediated Neurotoxicity: A Novel Candidate for HIV Neuroprotection

(2011) Stephanie A. Cross et al.   JOURNAL OF IMMUNOLOGY

Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity

(2011) C. Akay et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Activation status of integrated stress response pathways in neurones and astrocytes of HIV-associated neurocognitive disorders (HAND) cortex

(2011) C. Akay et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

(2010) Marlene Smurzynski et al.   AIDS

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

(2009) Christina M Marra et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals

(2009) Aylin Yilmaz et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

(2009) Annemarie M.J. Wensing et al.   ANTIVIRAL RESEARCH

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

(2009) Aylin Yilmaz et al.   PLoS One